First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma
/in Cervical Cancer, International Publications /von 2005-08-15 / Cancer 2005 Aug;104(4):763-70Prognostic significance of CD83 positive, mature dendritic cells in the gallbladder carcinoma
/in Gallbladder Cancer, International Publications /von 2005-08-01 / Oncol. Rep. 2005 Aug;14(2):353-6Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment
/in Dendritic Cells, Glioblastoma, International Publications /von 2005-08-01 / Clin. Cancer Res. 2005 Aug;11(15):5515-25Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein
/in International Publications, Newcastle Disease Virus /von 2005-08-01 / Int. J. Oncol. 2005 Aug;27(2):377-84Immunotherapy in multiple myeloma–possibility or probability?
/in International Publications, Malignant Lymphoma /von 2005-08-01 / Br. J. Haematol. 2005 Aug;130(3):344-62Dynamic control of lymphocyte trafficking by fever-range thermal stress
/in Hyperthermia, International Publications /von 2005-07-26 / Cancer Immunol. Immunother. 2006 Mar;55(3):299-311Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells
/in Colorectal Cancer, International Publications, NSCLC /von 2005-07-21 / Cancer Immunol. Immunother. 2006 Mar;55(3):268-76Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro
/in Colorectal Cancer, International Publications /von 2005-07-15 / J. Immunol. 2005 Jul;175(2):820-8Adjuvant IL-15 does not enhance the efficacy of tumor cell lysate-pulsed dendritic cell vaccines for active immunotherapy of T cell lymphoma
/in International Publications, Malignant Lymphoma /von 2005-07-15 / Cancer Immunol. Immunother. 2006 Apr;55(4):420-32IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de